Denmark's Genmab has decided not to continue the development of a drug for cancer, acasunlimab, which had reached phase 3 testing, after a review of its medicines pipeline. The decision to end the ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...
AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said. ・Genmab assumed sole responsibility for the ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan, for the treatment of small-cell lung cancer (SCLC), according to a news ...
Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.
Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback